Spedra to be Launched in UK

Spedra to be Launched in UK

In the coming weeks a new treatment for erectile dysfunction will be launched in the UK. Given the history of the EMAs strict regulations, and the time it generally takes to approve a treatment, it is hard not to be excited about this news. In this article we consider what is currently known about the new treatment.

The treatment, which goes by the name Spedra, will be made available in dosages of 50 mg, 100 mg and 200 mg. In addition to that, the packs will contain four, eight and twelve tablets. Similarly to its main competitors, Viagra, Cialis and Levitra, the new treatment will be using so-called PDE5 inhibitors. According to press releases from the manufacturer, the treatment is intended to start working approximately 12 minutes after being taken.

The main difference between Spedra and its competitors is currently unknown. This is mainly due to lack of data from comparative studies. However, based on 3 separate placebo-controlled trials in three separate populations, there is little evidence to suggest the efficacy of the treatment should be questioned at this stage. The main populations the treatment has been tested in include patients with erectile dysfunction as a primary concern, as well as patients exhibiting erectile dysfunction as a result of co-morbidities such as diabetes and prostatectomy.

We aim to provide updates on this exciting development as more data emerges.